Related Experiment Video
Updated: Apr 28, 2026
07:36
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
4.9K
Recent research and future prospects for gemtuzumab ozogamicin: could it make a comeback?
Carol O'Hear1, Jeffrey E Rubnitz
1Department of Oncology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 260, Memphis, TN 38105-2794, USA.
Expert Review of Hematology
|May 30, 2014
Summary
Gemtuzumab ozogamicin (GO) showed clinical benefit in certain acute myeloid leukemia (AML) patient subgroups, despite earlier withdrawal. These findings support CD33 as a viable therapeutic target for AML.
Area of Science:
- Oncology
- Immunotherapy
- Pharmacology
Background:
- Gemtuzumab ozogamicin (GO), an anti-CD33 antibody-drug conjugate, received accelerated FDA approval for acute myeloid leukemia (AML).
- GO was later withdrawn due to toxicity and lack of benefit in a Phase III trial.
- Subsequent trials revealed clinical benefits in specific AML patient subgroups.
Related Concept Videos
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K